Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector

Vaccine

Volumn 27, Issue 30, 2009, Pages 3992-4000

  Miller, John P ^a   Geng, Yongzhi ^a   Ng, Hwee L ^a   Yang, Otto O ^a   Krogstad, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coxsackievirus B3; HIV 1; Vaccine

Indexed keywords

CAPSID PROTEIN; COXSACKIEVIRUS B VECTOR; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MATRIX PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMINO ACID SEQUENCE; ARTICLE; CD8+ T LYMPHOCYTE; CODON; CONTROLLED STUDY; COXSACKIE VIRUS B; DNA MODIFICATION; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LYMPHOCYTE CLONE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE CULTURE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS REPLICATION;

BASE COMPOSITION; CELL LINE; CODON; ENTEROVIRUS B, HUMAN; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; GENOMIC INSTABILITY; HIV-1; HUMANS; VIRUS ASSEMBLY;

EID: 67349224723     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.035     Document Type: Article

References (36)

1. Fletcher P.S., Wallace G.S., Mesquita P.M., and Shattock R.J. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 3 1 (2006) 46
2. Shattock R.J., and Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1 1 (2003) 25-34
3. Tao W., Richards C., and Hamer D. Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses 24 7 (2008) 925-929
4. Van Damme L., Govinden R., Mirembe F.M., Guedou F., Solomon S., Becker M.L., et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359 5 (2008) 463-472
5. Nonoxynol-9 does not protect against HIV. AIDS Patient Care STDS 2008:22(1):p. 89-93.
6. HVTN Press Release (http://www.hvtn.org/media/pr/step1207.html); 2007.
7. McMichael A.J. HIV vaccines. Annu Rev Immunol 24 (2006) 227-255
8. Nathanson N., and Mathieson B.J. Biological considerations in the development of a human immunodeficiency virus vaccine. J Infect Dis 182 2 (2000) 579-589
9. Grossman Z., Meier-Schellersheim M., Paul W.E., and Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 12 3 (2006) 289-295
10. Crotty S., and Andino R. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv Drug Deliv Rev 56 6 (2004) 835-852
11. Crotty S., Lohman B.L., Lu F.X., Tang S., Miller C.J., and Andino R. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J Virol 73 11 (1999) 9485-9495
12. Crotty S., Miller C.J., Lohman B.L., Neagu M.R., Compton L., Lu D., et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 75 16 (2001) 7435-7452
13. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., and Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59 (2005) 587-635
14. Halim S.S., Collins D.N., and Ramsingh A.I. A therapeutic HIV vaccine using coxsackie-HIV recombinants: a possible new strategy. AIDS Res Hum Retroviruses 16 15 (2000) 1551-1558
15. Feuer R., Mena I., Pagarigan R., Slifka M.K., and Whitton J.L. Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 76 9 (2002) 4430-4440
16. Slifka M.K., Pagarigan R., Mena I., Feuer R., and Whitton J.L. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 75 5 (2001) 2377-2387
17. Ali A., Jamieson B.D., and Yang O.O. Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses. J Virol Methods 110 2 (2003) 137-142
18. Schneider R., Campbell M., Nasioulas G., Felber B.K., and Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71 7 (1997) 4892-4903
19. Yang O.O., Church J., Kitchen C.M., Kilpatrick R., Ali A., Geng Y., et al. Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins. J Virol 79 24 (2005) 15368-15375
20. Sabado R.L., Kilpatrick S., Ali A., Dagarag M., Ng H.L., Cao H., et al. Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides. J Immunol Methods 296 1-2 (2005) 1-10
21. Bennett M.S., Ng H.L., Dagarag M., Ali A., and Yang O.O. Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol 81 10 (2007) 4973-4980
22. Adnan S., Balamurugan A., Trocha A., Bennett M.S., Ng H.L., Ali A., et al. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 108 10 (2006) 3414-3419
23. Yang O.O., Kalams S.A., Rosenzweig M., Trocha A., Jones N., Koziel M., et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 70 9 (1996) 5799-5806
24. Yusim K., Kesmir C., Gaschen B., Addo M.M., Altfeld M., Brunak S., et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76 17 (2002) 8757-8768
25. Lee S.G., Kim D.Y., Hyun B.H., and Bae Y.S. Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system. J Virol 76 4 (2002) 1649-1662
26. Porter D.C., Melsen L.R., Compans R.W., and Morrow C.D. Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. J Virol 70 4 (1996) 2643-2649
27. Anton P.A., Ibarrondo F.J., Boscardin W.J., Zhou Y., Schwartz E.J., Ng H.L., et al. Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. Vaccine 26 35 (2008) 4617-4623
28. Koup R.A., Sullivan J.L., Levine P.H., Brettler D., Mahr A., Mazzara G., et al. Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood 73 7 (1989) 1909-1914
29. Walker B.D., Flexner C., Birch-Limberger K., Fisher L., Paradis T.J., Aldovini A., et al. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86 23 (1989) 9514-9518
30. Mandl S., Sigal L.J., Rock K.L., and Andino R. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc Natl Acad Sci USA 95 14 (1998) 8216-8221
31. Mueller S., and Wimmer E. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames. J Virol 72 1 (1998) 20-31
32. Pilipenko E.V., Gmyl A.P., and Agol V.I. A model for rearrangements in RNA genomes. Nucleic Acids Res 23 11 (1995) 1870-1875
33. Whitton J.L., Cornell C.T., and Feuer R. Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 3 10 (2005) 765-776
34. Henke A., Huber S., Stelzner A., and Whitton J.L. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 69 11 (1995) 6720-6728
35. Tracy S., and Gauntt C. Group B coxsackievirus virulence. Curr Top Microbiol Immunol 323 (2008) 49-63
36. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15 3 (2009) 293-299